08:03 AM EDT, 09/19/2022 (MT Newswires) -- Virios Therapeutics (VIRI) shares sank 60% premarket Monday, after the company said a phase 2b study of IMC-1 to treat fibromyalgia did not achieve statistical significance on the primary efficacy endpoint.
Panbela Therapeutics (PBLA) shares plunged 29%, after surging 53% on Friday.
IBio (IBIO) shares plummeted 17%, following Friday's hefty gains.
Nexalin Technology (NXL) shares dropped 16%, adding to losses on its market debut on Friday.
Innate Pharma (IPHA) shares fell 15%, giving back most of Friday's gain.